H.C. Wainwright Maintains Caribou Biosciences(CRBU.US) With Buy Rating, Cuts Target Price to $3
HC Wainwright & Co. Maintains Buy on Caribou Biosciences, Lowers Price Target to $3
New Analyst Forecast: $CRBU Given 'Buy' Rating
Express News | Caribou Biosciences, Inc. : H.c. Wainwright Cuts Target Price to $3 From $9
Caribou to Prioritize Lead Cancer Programs in Portfolio Shakeup
Express News | Caribou Biosciences Inc - to Present Data From CB-010 and CB-011 in H2 2025
Express News | Caribou Biosciences Inc - Changes Expected to Extend Cash Runway Into H2 2027
Express News | Caribou Biosciences Inc - Discontinues Gallop Phase 1 Trial of CB-010 for Lupus
Express News | Caribou Biosciences Inc - to Reduce Workforce by 32%
Caribou Biosciences Announces Strategic Pipeline Prioritization With Focus on CB-010 and CB-011 Oncology Programs
Truist Financial Maintains Caribou Biosciences(CRBU.US) With Buy Rating
Analysts Offer Insights on Healthcare Companies: Caribou Biosciences (CRBU), Olema Pharmaceuticals (OLMA) and Privia Health Group (PRVA)
Truist Financial Remains a Buy on Caribou Biosciences (CRBU)
Truist Removes Price Target on Caribou Biosciences, Keeps Buy Rating; Price Target Was $19
Express News | HC Wainwright & Co. Reiterates Buy on Caribou Biosciences, Maintains $9 Price Target
Caribou Biosciences Analyst Ratings
Director Makes Bold Move With Major Stock Purchase in Caribou Biosciences!
Insider Purchase: President and CEO of $CRBU Buys 20,000 Shares
Analysts Remain Bullish on Caribou Biosciences (CRBU) Despite Ongoing Slump in Its Shares
Evercore Maintains Caribou Biosciences(CRBU.US) With Hold Rating, Maintains Target Price $3